Relief from neuropathic pain by blocking of the platelet-activating factor-pain loop.
Shindou H, Shiraishi S, Tokuoka SM, Takahashi Y, Harayama T, Abe T, Bando K, Miyano K, Kita Y, Uezono Y, Shimizu T.
Shindou H, et al. Among authors: kita y.
FASEB J. 2017 Jul;31(7):2973-2980. doi: 10.1096/fj.201601183R. Epub 2017 Mar 24.
FASEB J. 2017.
PMID: 28341636
Free PMC article.
In conclusion, LPCAT2 is a novel therapeutic target for newly categorized analgesic drugs; in addition, our data call for the re-evaluation of the clinical utility of PAF receptor antagonists.-Shindou, H., Shiraishi, S., Tokuoka, S. M., Takahashi Y., Harayama, T., Abe, T., …
In conclusion, LPCAT2 is a novel therapeutic target for newly categorized analgesic drugs; in addition, our data call for the re-evaluation …